Longevity UniversityAsk the evidence

Is there human evidence for BPC-157?

Answered November 2, 20268 sources

EvidenceDPreliminaryVery uncertain: animal or cell studies, or studies in people with several serious weaknesses.

Yes, but very little: three small studies with 30 people in all, none with a comparison group. Most people reported feeling better, though these studies can't show the peptide caused it.

Who it's for
No group has a clear benefit; people with knee or bladder pain were studied.
What to expect
Symptom relief was reported, but the size is unknown and unproven.
Watch out for
Safety is poorly known, and it isn't approved for human use.

What the studies show

  • A systematic review A review that searches for every study on a question in a set way and weighs them together, rather than picking a few. found only three human studies of BPC-157, covering 30 people. They included knee pain (16 people, injected into the joint), interstitial cystitis (a painful bladder condition, 12 people, given into the bladder) and an intravenous safety test (2 people)1.
  • All three reported symptom improvement in most people and no side effects linked to treatment. The review rated all three poor quality and the overall certainty very low1.
  • None had a dummy pill (placebo A dummy treatment that looks like the real one, so people can't tell which they got.) group or a comparison group, so improvement could stem from chance, the natural course of the pain, or expectation. None used a standardized pharmaceutical preparation1,4.
  • A separate review describes no completed Phase II trial, no approved formulation and no validated dose4. In the two-person human pilot and in animals, the peptide cleared from blood in under 30 minutes4.
  • Nearly all the animal work, which shows healing of tendon, muscle and bone in rodents, comes from one research group in Zagreb. Animal results can't stand in for human results2,3,4.
  • A lab study of 12 pieces of human artery, taken from bypass surgery, found BPC-157 relaxed the vessel, mostly through nitric oxide. This is tissue in a dish, not a treatment test in people5.
  • Two controlled trials are registered, one in hamstring strain (120 people) and one after rotator cuff surgery (30 people). Both are testing the question, with no results yet7,8.

Key studies

StudyWhoWhat it found
Review of 3 human studies, 2026130 people with knee or bladder pain, or in a safety testMost improved, no treatment-linked side effects; poor quality, very low certainty
Narrative review, 20264Fewer than 30 people in three uncontrolled pilotsNo approved formulation, no validated dose, no Phase II trial
Lab study of human arteries, 20265Artery pieces from 12 bypass patientsVessel relaxation, mainly via nitric oxide
Review of animal and pilot data, 20262Animal models, small human pilotsHealing in animals; human data limited; trials needed

Safety

The FDA lists BPC-157 among substances that may pose significant safety risks in compounding. It cites possible immune reactions, impurities and unclear ingredient makeup, and says there isn't enough information to know whether it harms people6. A review raises a theoretical concern about tumor growth in abnormal tissue, though this is speculative and the peptide slowed tumor growth in some cell lines3. The small human studies reported no treatment-related side effects, but 30 people can't rule out harm1.

What we don't know

  • Whether it works at all in people, since no controlled human trial has reported results.
  • What dose is safe and effective, and what long-term use does.

Ask a follow-up

More on peptides

Written by AI from the studies listed, without review by a clinician, and graded with the GRADE method. It can be wrong, so check the studies it cites. Education, not medical advice.